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http://www.biomedcentral.com/1471-2431/13/108STUDY PROTOCOL Open AccessDoesmetformin improve vascular health in children
with type 1 diabetes? Protocol for a one year,
double blind, randomised, placebo controlled trial
Jemma Anderson1,2*, Alexia S Peña1,2, Thomas Sullivan3, Roger Gent4, Bronwen D’Arcy5, Timothy Olds6,
Brian Coppin7 and Jennifer Couper1,2Abstract
Background: Cardiovascular disease is the leading cause of mortality in Type 1 diabetes (T1D). Vascular dysfunction
is an early and critical event in the development of cardiovascular disease. Children with T1D have vascular
dysfunction therefore early interventions to improve vascular health are essential to reduce cardiovascular mortality
in T1D. Metformin is an insulin sensitising agent which is known to improve vascular health outcomes in type 2
diabetes (T2D) and other individuals with insulin resistance. It has been used safely in children and adolescents with
T2D for over 10 years. This study aims to assess the effect of metformin on vascular health in children with T1D.
Methods/Design: This study is a 12 month, double blind, randomised, placebo controlled trial to determine the
effect of metformin on vascular health in children (age 8–18) with T1D. The sample size is 76 with 38 children in
the metformin group and 38 children in the placebo group. Vascular health and biochemical markers will be
measured at baseline, 3, 6 and 12 months. Vascular function will be measured using flow mediated dilatation and
glyceryl trinitrate mediated dilatation of the brachial artery and vascular structure will be measured with carotid and
aortic intima media thickness, using standardised protocols.
Discussion: This study will be the first to investigate the effect of metformin on vascular health in children with
T1D. It will provide important information on a potential intervention to improve cardiovascular morbidity and
mortality in this population at high risk from cardiovascular disease.
Trial registration: Australia New Zealand Clinical Trials Registry ACTRN12611000148976
Keywords: Endothelial function, Metformin, Type 1 diabetes, ChildBackground
Vascular dysfunction and cardiovascular disease in Type 1
diabetes
XCardiovascular disease remains the leading cause of
mortality in Type 1 Diabetes (T1D), despite significant
developments in management over the past 20 years
[1,2]. Children with T1D have evidence of cardiovascular
abnormalities such as vascular endothelial and smooth
muscle dysfunction and increased intima media thickness
[3-5]. Vascular dysfunction precedes clinically evident* Correspondence: jemma.anderson@adelaide.edu.au
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reproduction in any medium, provided the orvascular disease [6] and is potentially reversible. Although
vascular complications are rarely seen during childhood,
their pathogenesis begins soon after diagnosis and accele-
rates during puberty [7]. Vascular dysfunction in T1D is
also accelerated by poor glycaemic control, overweight
and obesity, genetic predisposition and insulin resistance.
Early interventions to improve cardiovascular health in
T1D are essential to reduce the burden of cardiovascular
morbidity and mortality.
The doubling in incidence of T1D in childhood in
Australia over the last 20 years parallels the overweight/
obesity epidemic in Western childhood populations. In
addition, age of diagnosis of T1D has decreased over the
last 20 years and younger age of T1D onset is associated
in some populations with higher Body Mass Index (BMI)ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the population shift in BMI, with 65% of adults in a US
cohort with T1D in the overweight or obese BMI range
[10]. Higher BMI is associated with higher intima media
thickness (IMT) blood pressure and dyslipidaemia [11].
The prevalence of overweight and obesity in children
with T1D is higher than the normal population, at just
over 38.5% in a Dutch cohort [12], 22.1% in a US cohort
(compared with 16.1% in the normal population) [13]
and 31% in our local South Australian cohort [14]. This
is associated with other cardiovascular risk factors
including hypertension, dyslipidaemia, and metabolic
syndrome. Overweight and obesity may have additional
clinical consequences with the associated higher insulin
resistance contributing to vascular disease [12,15].
Adolescence is a critical time in determining risk of
future vascular complications [16] and is a time when
vascular dysfunction is potentially reversible. Optimisa-
tion of diabetes control should be the initial strategy to
improve vascular health in children and adolescents with
T1D. However, glycosylated haemoglobin (HbA1c) levels
are higher than target levels recommended for prevention
of complications [17,18]. This is despite the advances in
insulin delivery with insulin analogues and continuous
subcutaneous insulin infusion (CSII) [19], highlighting the
need to identify additional vascular protective strategies to
prevent cardiovascular disease at its inception. The aim of
this study is to determine whether metformin improves
vascular health in children with T1D.
Assessment of vascular health
Vascular function
The endothelium is a key regulator of vascular function
[20] and endothelial dysfunction occurs early in the deve-
lopment of atherosclerosis [21]. Vascular dysfunction can
be measured by Flow Mediated Dilatation (FMD) and
Glyceryl Trinitrate mediated Dilatation (GTN). These are
early, non-invasive markers of atherosclerosis and predate
the development of clinically evident disease [22,23].
Ultrasound assesses brachial artery responses to in-
creased blood flow (FMD). This induces nitric oxide re-
lease from the endothelium with a resultant increase in
brachial artery diameter and is a measure of endothelial
function. Exogenous administration of glyceryl trinitrate
increases vessel diameter independent of the endothelium
and is a measure of smooth muscle function (GTN). FMD
and GTN have proven to be accurate and reproducible
methods for assessment of vascular function [24].
Endothelial dysfunction of the coronary arteries, as mea-
sured by coronary artery vasomotor responses, is asso-
ciated with a higher incidence of cardiovascular events in
adulthood. FMD of the brachial artery relates to both
coronary artery vasomotor responses and to the extent of
coronary artery disease on coronary angiography findings[25]. Reduced FMD in adults relates to traditional cardio-
vascular risk factors [22]. FMD is abnormal in children
and young adults at risk of atherosclerosis [23]. FMD and
GTN will be outcome measures in this study.
Vascular structure
The thickness of the intima and media layer of the carotid
(cIMT) and aortic (aIMT) walls are structural markers of
atherosclerosis and can be evaluated by ultrasound.
cIMT is a well-established index of early atheroscler-
osis that correlates with prevalent and incident coronary
heart disease and stroke [26]. Relative risk of stroke or
myocardial infarction in older adults without a history of
cardiovascular disease increases by 35% with an increase
in cIMT of 1 SD, i.e. a relatively large clinical effect for a
small change in cIMT [26]. Overweight and obese chil-
dren have increased cIMT compared with age matched
controls [27]. cIMT has been used as a primary outcome
measure in landmark intervention trials [7,28]. Diet and
exercise improve endothelial dysfunction and reduce
cIMT in obese children over 12 months [29]. In this
study FMD improved early and was maintained and
cIMT improved at 12 months. Atherosclerosis begins in
the abdominal aorta. We and others have shown that
aIMT precedes changes in cIMT in children with acceler-
ated atherosclerosis, including T1D [3,4]. cIMT and aIMT
will be used in this study as structural outcome measures.
Adiponectin
Adiponectin is an adipocytokine that regulates nitrous
oxide by activating endothelial nitric oxide synthase. It
may provide a measurable link between visceral obesity,
insulin resistance and vascular dysfunction. We have
shown that adiponectin levels relate to vascular smooth
muscle function in obese youth [30]. Adiponectin/leptin
ratio is an emerging measure of insulin resistance and is
substantially higher in children with type 2 compared
with type 1 diabetes [31,32].
Metformin as a therapy to improve vascular health
Mechanism of action
Metformin is a biguanide that reduces glucose output
from the liver and increases insulin sensitivity. Met-
formin activates the energy regulating AMP activated
protein kinase (AMPK), principally in muscle and liver.
This is the major mechanism of metformin’s action, to
increase insulin stimulated glucose uptake in skeletal
muscle and adipocytes, and reduce hepatic glucose out-
put. Metformin also activates AMPK in the endothelium
and smooth muscle. This is likely to explain the im-
provement in endothelium dependent and independent
vascular responses with the administration of metformin
in adults with T1D and polycystic ovarian syndrome
[33-35]. It may also explain the recognised benefits of
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cose lowering effect. Metformin also improves adiponectin
and leptin levels [35-37].
Type 2 diabetes
Metformin is the first line medication (with diet and ex-
ercise) in youth with type 2 diabetes (T2D) and/or with
metabolic syndrome [38]. In T2D it improves endothelial
function, decreases weight gain, triglycerides, LDL chol-
esterol and pro-inflammatory and pro-coagulation fac-
tors [39,40]. Importantly, in two large randomised trials
metformin reduced the rate of myocardial infarction in
adults with T2D by 33%. Metformin also improves BMI,
body composition and fasting insulin in obese youth
without diabetes [41,42].
Type 1 diabetes
A 6 month pilot study reported improvements in vascu-
lar health, as measured by FMD, in 44 adults with T1D
treated with metformin or placebo in addition to insulin
[33]. Meta-analysis of randomised studies of metformin
in T1D shows benefits in reducing daily insulin require-
ment and reduced weight gain [43]. The potential bene-
fit on improving LDL cholesterol is not confirmed and
reductions in HbA1c are inconsistent.
There are only two studies in children using metformin
in addition to insulin. They show that metformin lowered
HbA1c and decreased insulin dose without weight gain in
children with poor metabolic control [44,45].
Therefore, metformin is a logical adjunct treatment for
T1D in addition to insulin. There are no data on the
effects of metformin on vascular health in children and
adolescents with T1D. We have shown that children
with T1D have severe vascular dysfunction which relates
to BMI [14]. We will therefore determine the effect of
metformin on vascular function and structure in chil-
dren with T1D and above average BMI, in the absence
of any published trials.
Aims and hypotheses
The primary objective of this double blind, randomised,
placebo controlled trial is to determine whether metfor-
min improves vascular function as measured by FMD in
children aged 8–18 years who have T1D.
The secondary objectives are to determine the effect of
metformin on vascular health as measured by GTN,
cIMT and aIMT in addition to other variables including
adiponectin/leptin ratio, waist circumference, BMI, body
composition, insulin requirements, HbA1c and lipids.
We hypothesise that the intervention group (those that
receive metformin) will have a significant improvement
in vascular health compared to the placebo group. We
also hypothesise that those in the intervention group will
have improvements in adiponectin/leptin ratio, waistcircumference, BMI, body composition, insulin require-
ments, HbA1c and lipids.
Methods/design
Approval and registration
This study is a parallel, double blind, randomised placebo
controlled trial over 12 months in two paediatric diabetes
centres in Adelaide, South Australia. The trial has been ap-
proved by the Women’s and Children’s Hospital Research
Ethics Committee (HREC 2327/12/13) and Flinders Med-
ical Centre Research Ethics Committee (HREC 443.12) and
is prospectively registered with the Australian New Zealand
Clinical Trials Registry (ACTRN12611000148976).
All children with T1D who are seen in the diabetes out-
patient clinics of the Women’s and Children’s Hospital
(WCH) and Flinders Medical Centre (FMC) paediatrics
department will be approached consecutively to be
screened for eligibility in the study.
A total sample of 76 children aged 8–18 years with T1D
will be recruited. The treatment period is 12 months in
duration. Written informed consent will be obtained from
all parents of participants and written assent will be
obtained from all participants.
Inclusion criteria
Each child must meet the following criteria to be involved
in this study:
 diagnosed with type 1 diabetes
 aged between 8 and 18 years.
 BMI > 50th centile for age and sex [Centers for
Disease Control and Prevention 2000 standardized
reference charts (http://wwwn.cdc.gov/epiinfo/)].
 T1D duration greater than 1 year
 insulin requirements > 0.5 units /kg/day to exclude
subjects in the remission phase of T1D
Exclusion criteria
Children are excluded from the study if they meet any of
the following criteria:
 non T1D i.e. T2D or other forms of diabetes
 severe hypoglycaemic episode in preceding
6 months defined as a loss of consciousness or
convulsion associated with hypoglycaemia
 recurrent diabetic ketoacidosis (more than 2
episodes in the preceding year)
 other serious co-morbidities but not including
treated hypothyroidism or coeliac disease
 contraindications to metformin therapy:
hypersensitivity to metformin, renal or liver
dysfunction, vitamin B12 deficiency, inability to
abstain from alcohol
 pregnancy or breast feeding
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anti-hypertensives
Randomisation
The study has a planned sample size of 76 with 38 in each
group. Randomisation was performed by an independent
statistician using statistical software S-plus version 8.1 to
provide equal representation of placebo and metformin.
Allocation concealment was used to implement the ran-
dom sequence allocation.
Participants will be recruited from paediatric outpatient
clinics at WCH and FMC by a single investigator (JA).
Participants will be assigned randomisation numbers by
the investigator in sequence and allocated to a treatment
group by the pharmacist using the generated randomisa-
tion list. Treatment allocation will be concealed from all
study investigators, the distributing pharmacist and partic-
ipants to minimise potential bias.
Analysis of the data will be performed by a statistician
(TS) who was not involved in the initial randomisation.
Participant withdrawal
Any participant may terminate participation in the study
without giving a reason and without any disadvantage or
interference with the diabetes care provided to the partici-
pant at the treating hospital. An investigator can stop the
participation of a subject after consideration of the be-
nefit/risk ratio of participation in the trial. Reasons to stop
participation include: serious adverse events, request












Figure 1 Study procedure details.reasons and limitation to continue the trial such as a par-
ticipant moving interstate.
Treatment arms and dosage of medication
The children will receive either metformin or placebo
according to their randomly allocated group. The study
procedure details are outlined in Figure 1. Metformin
500 mg oral tablets will be supplied by GenericHealth
(Camberwell, Victoria, Australia). The placebo will be also
supplied by the same company and is identical in appear-
ance and ingredients, aside from the active ingredient,
metformin hydrochloride. If the participant’s weight is less
than 60 kg they will be assigned to a dosage of 500 mg
twice a day (titrated up over 2 weeks). If the participant
weighs greater than 60 kg they will be assigned to a dosage
of 1 g twice a day (titrated up over 6 weeks). Dose titration
will be limited to tolerance of the medication. If a partici-
pant experiences a reduction in insulin dose of greater
than 20%, or if they have persistent gastrointestinal side ef-
fects, they will be prescribed the maximum tolerated dose.
Both groups will also receive a dietary intervention at
the commencement of the study and at 3 months. At
the first visit, all subjects will receive standardised infor-
mation regarding healthy diet, portion sizes, regular
meals and physical activity. This information will be
delivered using a ‘Type 1 diabetes and healthy weight’
resource Additional file 1), developed by our dietician
(BD) using current guidelines for healthy eating in T1D.
At the 3 month assessment, all participants will take part
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snack foods to ‘sometimes’ and ‘treat’ snack foods.Outcome measures
Table 1 shows which primary and secondary outcomes
will be measured at different time points in the study.
Table 2 shows additional information which will be col-
lected at the assessments and Table 3 shows the additional
information collected at each telephone call (which occurs
2 weekly for the first 3 months and monthly thereafter).Ultrasound assessment of vascular function (FMD and
GTN) and vascular structure (cIMT and aIMT)
Experienced and blinded sonographers (trained and led
by RG) will perform all B mode ultrasound examinations
with a 17–5 MHz linear array transducer (iU22; Phillips,Table 1 Primary and secondary outcome measures
Primary outcome
Vascular endothelial function (FMD)
Secondary outcomes
Vascular smooth muscle function (GTN)
Vascular structure (cIMT and aIMT)
Physical examination
- anthropometric measurements (height, weight, BMI, waist circumference)
- the presence of acanthosis nigricans
- severity of acne
- ferriman - gallwey score (girls)





High sensitivity C-Reactive Protein (HsCRP)
Early morning urinary albumin/creatinine
Urinary prostaglandin F2α
Liver function, renal function tests and lactate
Total Plasma homocysteine
Girls only: Testosterone, free androgen index, Sex Hormone-Binding
Globulin, Dehydroepiandrosterone, Anti-Mullerian Hormone, 17-hydroxy




Body composition (bio-electrical impedance analysis
using Tanita body composition scales)
Retinal photograph
Total body Dual-energy X-ray absorptiometry scan
*Indicates assessment of a variable at the timepoint indicated.Bothel, Washington, USA) in a temperature-controlled
room (22–24°C).
Flow mediated dilatation (FMD) and glyceryl trinitrate
mediated dilatation (GTN)
FMD and GTN will be assessed as previously described
[3,14,46,47]. Ultrasound images of the brachial artery in
longitudinal section, 2–15 cm above the elbow will allow
measurements of the arterial diameter. Each study will
include 4 scans: (1) resting scan; subsequently, reactive
hyperaemia is induced by occluding arterial blood flow
using a sphygmomanometer inflated to 250 mmHg for
4 minutes; (2) FMD scan recorded between 45–75 sec-
onds after cuff deflation; (3) re-control scan 10–15 mi-
nutes later (allowing for vessel recovery); and (4) last
scan, taken 4 minutes after the sublingual administration
of the GTN spray (400 μg, Nitrolingual Pump spray,Baseline 3 months 6 months 12 months
* * * *
* * * *
* *
* * * *
* * * *
* * * *
* * * *
* * * *
* * * *
* * * *
* * * *
* * * *
* * * *
* * * *
* * * *
* * * *
* * * *
* * * *
* *
* *
Table 2 Additional information collected at assessments
Baseline 3 months 6 months 12 months
ACAES questionnaire v1.2 * * * *
Physical examination – tanner stage * * * *
Daily energy expenditure (SenseWear arm band) * * * *
Family history of premature cardiovascular disease * *
Pregnancy test in post menarchal girls * * * *
Serum cotinine * * * *
Adherence data using MEMS caps and manual tablet count * * * *
Serum Vitamin B12, Folate, red cell folate * * * *
* Indicates assessment of a variable at the timepoint indicated.
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Hohenlockstedt, Germany, distributed by Sanofi-Aventis,
Macquarie Park, NSW, Australia). For each scan, mea-
surements will be made over 4 consecutive cardiac cycles,
incident with the R wave on the ECG (i.e., at the end of
diastole), by observers blinded to the intervention type,
using ultrasonic calipers. Measurements will be averaged
and expressed as percentages of the resting scan. Our co-
efficient of variation (CV) between 20 controls is 3.9% for
FMD and 4.0% for GTN-mediated dilatation [46].
Carotid and aortic intima media thickness (cIMT and aIMT)
cIMT and aIMT will be assessed as previously described
[3,48]. In brief, the left and right common carotid artery
will be imaged in a standardized magnification (2 ×
2 cm) using images of the posterior (far) wall of the dis-
tal 10 mm of the common carotid artery, just proximal
to the carotid bulb. Optimal images will be captured at
the end of diastole, incident with the R-wave of the
ECG, for later analysis. The greatest distance between
the lumen-intima interface and media –adventitia inter-
face (IMT) is measured using an automatic edge detec-
tion and measurement computer software package, and
mean and maximum IMT are recorded. The mean of 2
measurements for aIMT and 6 measurements (3 on each
side) for cIMT will be calculated according to the
current Gold Standard protocol for cIMT. Analysis will
be by two blinded observers. Sonographers have been
trained and have undergone an accreditation process toTable 3 Additional information collected with each phone
call
0-3 months 3-12 months




- hypoglycaemia (number, severity)
- gastrointestinal symptoms
(nausea, vomiting, diarrhoea, anorexia)
- rash
- other side effects
Insulin requirementsevaluate the quality of their scans for this study in 2009.
Our inter-observer intra-class coefficient for cIMT mea-
surements is 0.99 (CV 1.2%) and the intra-observer
intra-class coefficient for cIMT measurements is 0.97
(CV 2.4%) [3].
Physical examination
Weight and body composition will be measured in light
clothing using BC-418 segmental body composition ana-
lyser (Tanita, Tokyo, Japan distributed by Wedderburn,
Inglewood, NSW, Australia). Height will be measured on
a wall mounted stadiometer (to 0.1 cm). Waist and hip
circumference will be measured with a tape (to 0.5 cm).
Waist circumference will be measured at the midpoint be-
tween the lower edge of the ribs in the mid-axillary line
and the top of the iliac crest, at minimal respiration. Hip
circumference will be measured at the maximum circum-
ference of the buttocks with the tape parallel to the floor.
BMI z score will be calculated using 3.2 EpiInfo data-
base version.2 and Centers for Disease Control and Pre-
vention 2000 standardized reference charts (http://
wwwn.cdc.gov/epiinfo/). Blood pressure will be mea-
sured using DINAMAP (Carescape V100 Vital signs
monitor, GE Healthcare, Milwauke, WI) with
appropriate-size cuff on the left arm after 10 minutes of
rest in supine position. The mean of 3 consecutive mea-
surements will be recorded.
Laboratory methods
Cholesterol (LDL and HDL) and triglycerides will be
measured using commercial enzymatic assays on Roche/
Hitachi cobas C systems. High sensitivity C reactive
protein (hs CRP) will be measured using a near infrared
particle immunoassay method using IMMAGE Im-
munochemistry Systems Reagent (Beckman Coulter Inc,
Fullerton, California, USA). Glycosylated haemoglobin
(HbA1c) will be measured using a latex immunoagglu-
tination inhibition methodology (DCA 2000 Hemoglobin
A1c Reagent Kit; Bayer, Toronto, Ontario). Serum cotin-
ine will be measured using a cotinine micro-plate EIA
(STC Technologies). Urinary albumin/creatinine will be
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orimetric methods in routine laboratory assays. Oxida-
tive stress will be assessed by measuring urinary PGF2α
using a competitive enzyme-linked immunoassay and
values obtained will be corrected for urinary creatinine.
Liver function and renal function tests will be measured
by Roche/Hitachi cobas C systems.
Serum samples will be frozen at −80 degrees Celsius
for later measurement of adiponectin, leptin and andro-
gens. Total adiponectin and leptin will be analysed using
an enzyme-linked immunoassay (ALPCO diagnostics,
Salem, NH, USA). Serum androgens will be measured by
liquid chromatography mass spectroscopy (CPR Pharma
Services, Adelaide, South Australia).Total body dual-energy X-ray absorptiometry scan
The ratio of total body fat (g) to lean body mass (g) will
be measured using dual-energy X-ray absorptiometry
(DXA) on a GE-Lunar Prodigy machine (GE LunarCorp,
Maddison, WI) equipped with adult property software,
version 3.6, which is appropriate for body weight of sub-
jects 8–18 years. Fast scan mode and standard subject
positioning will be used for these measurements. Mean
precision of our machine is 1.3% for soft tissue.Assessment of energy intake and diet quality
The Australian Child and Adolescent Eating Survey
(ACAES – version 1.2) [49] is a food frequency ques-
tionnaire based on the previous 3–6 months of food
intake across all food categories. It will be interviewer-
administered by the same dietitian at each assessment.
At baseline, the ACAES will calculate the dietary intake
over the previous 6 months. At subsequent assessments
(3, 6 and 12 months) the ACAES questionnaire will calcu-
late the dietary intake since the previous assessment. The
ACAES will determine total caloric intake and macro and
micronutrient content of the participant’s diet.Assessment of energy expenditure
Daily energy expenditure will be measured at 0, 3, 6 and
12 months. This will be assessed with the use of a
SenseWear MF (Mini Form factor) device (analysed with
SenseWear Software Version 7.0. Temple Healthcare Pty
Ltd, Bowral, Australia) which is an external armband
worn in this study for 5 days before each assessment time
point. Based on measurements of accelerometry, heat
flux, galvanic skin response, skin temperature, near-body
temperature and patient characteristics (gender, age,
height, weight) proprietary algorithms will calculate
energy expenditure, number of steps taken and sleep
duration.Monitoring of safety and adverse events
Blood glucose management during study
All subjects will receive 2 weekly telephone review of
blood glucose control for the first 3 months and monthly
thereafter. They will also have access to a 24 hour phone
hotline serviced by one of 4 paediatric endocrinologists
for acute insulin dose adjustment.
Compliance assessment
Assessment of adherence to the study medication regi-
men will be assessed at each assessment time point
(3 months, 6 months and 12 months). All unused study
drugs will be returned to the investigator for counting.
MEMS caps (AARDEX group LTD, Sion, Switzerland)
will also be utilised to measure compliance. These caps
record how many times the study medication bottle is
opened between study visits and the data will be
downloaded for review and analysis. Compliance will be
encouraged at the 3 month and 6 month study visit
using the downloaded data from the MEMS cap.
Monitoring of adverse events
Renal, liver function tests and lactate will be performed
at 0, 3, 6 and 12 months. Metformin can decrease levels
of vitamin B12, so children with vitamin B12 deficiency
will be excluded and vitamin B12 will be monitored dur-
ing the study. The risk of hypoglycaemia will be moni-
tored and insulin will be adjusted accordingly.
Metformin can cause nausea and diarrhoea. Any ill-
ness or need for additional medication in a subject will
be recorded throughout the study. Letters to the sub-
jects’ endocrinologists and general practitioner advising
of entry into the trial will be sent, and the WCH and
FMC emergency departments will have a record of the
subject’s participation in the trial in the medical records.
All adverse events will be reported to the medication
safety committee for the trial in a monthly monitoring
update. All serious adverse events will be reported to the
medication safety committee and the WCH human re-
search ethics committee within 24 hours of the event
occurring. Serious adverse events occuring in FMC
participants will also be reported to the FMC human
research ethics committee. A serious adverse event is de-
fined as one which is fatal or life threatening or requires
hospitalization.
Data analysis
All analyses will be performed under the intention to treat
principle. The primary outcome, FMD, will be compared
between metformin and placebo groups over 12 months
using a linear mixed effects model. Linear mixed effects
models will also be used to compare changes in secondary
continuous outcomes (GTN, adiponectin/leptin ratio,
lipids, HbA1c, insulin requirements, cIMT and aIMT)
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four reviews. The linear mixed effects models will account
for the within-subject correlations that are produced when
repeating outcome measurements in individual subjects
over time. Both unadjusted and adjusted analyses will be
performed, with adjustment for important pre-specified
baseline covariates including age, sex and BMI.
While no studies have looked at the effect of metformin
on FMD in T1D in this age group, our previous work
found an improvement in FMD of 3.1% with an SD of 4.3
in children with T1D receiving folic acid over 8 weeks
[46,47]. Assuming an equivalent improvement with met-
formin from baseline to 12 months, we would require 32
subjects per group to have 80% power to detect a differ-
ence in FMD changes of 3.1% between randomised groups
(alpha = 0.05 two-sided). Our dropout rate in previous
studies in this population with similar intervention and in-
vestigation over 24 weeks has been 1–2%. We have con-
servatively factored in a dropout rate of 15% giving a total
recruitment required of 76 subjects (38 in each group).
Discussion
Cardiovascular disease is the commonest cause of morbid-
ity and mortality in T1D. The origins of cardiovascular dis-
ease are in childhood. Good metabolic control is essential
in the prevention of cardiovascular disease however targets
for optimal glycaemic control are often not met in children
and adolescents with T1D. It is crucial to investigate add-
itional effective and early interventions to prevent or reduce
vascular pathology in this population. Metformin is a good
candidate for early prevention of cardiovascular disease as
it has been prescribed in youth with T2D for over 10 years
and reduces cardiovascular disease in T2D.
Metformin is generally well tolerated and easy to admi-
nister with a good safety profile. Vascular health outcomes
will be measured using non invasive, valid and reliable
measurements by experienced investigators. This is, to our
knowledge, the first study to examine whether administra-
tion of metformin will improve vascular health in children
withT1D. Determining the effect of metformin on vascular
health in children with T1D will provide a potential early
intervention for cardiovascular disease in this population.
Additional file
Additional file 1: “Type 1 Diabetes and healthy weight” dietician
resource used for dietary intervention at baseline assessment.
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